1. Home
  2. ESRT vs TBPH Comparison

ESRT vs TBPH Comparison

Compare ESRT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Empire State Realty Trust Inc.

ESRT

Empire State Realty Trust Inc.

HOLD

Current Price

$5.55

Market Cap

913.4M

Sector

Real Estate

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.84

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESRT
TBPH
Founded
2011
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
913.4M
824.9M
IPO Year
2012
2013

Fundamental Metrics

Financial Performance
Metric
ESRT
TBPH
Price
$5.55
$16.84
Analyst Decision
Hold
Buy
Analyst Count
3
6
Target Price
$6.35
$18.40
AVG Volume (30 Days)
1.3M
331.2K
Earning Date
04-29-2026
05-04-2026
Dividend Yield
2.49%
N/A
EPS Growth
N/A
279.13
EPS
0.25
2.06
Revenue
$768,270,000.00
$15,386,000.00
Revenue This Year
$4.26
$8.46
Revenue Next Year
$1.52
N/A
P/E Ratio
$22.34
$8.14
Revenue Growth
0.05
N/A
52 Week Low
$4.87
$8.33
52 Week High
$8.76
$21.03

Technical Indicators

Market Signals
Indicator
ESRT
TBPH
Relative Strength Index (RSI) 54.12 56.35
Support Level $4.87 $16.14
Resistance Level $6.70 $17.24
Average True Range (ATR) 0.17 0.39
MACD 0.02 -0.00
Stochastic Oscillator 57.84 55.66

Price Performance

Historical Comparison
ESRT
TBPH

About ESRT Empire State Realty Trust Inc.

Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: